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What is the added value of digital image analysis of HER2 immunohistochemistry in breast
cancer in clinical practice? A study with multiple platforms
Aims: We aimed to compare digital image analysis
(DIA) of human epidermal growth factor receptor 2
(HER2) immunohistochemistry (IHC) in breast cancer
by two platforms: (i) to validate DIA against standard
diagnostics; and (ii) to evaluate the added value of
DIA in clinical practice.
Methods and results: HER2 IHC and in-situ hybridisa-
tion (ISH) were performed on 152 consecutive inva-
sive breast carcinomas. IHC scores were determined
with DIA using two independent platforms. Manual
scoring was performed by two independent observers.
HER2 status was considered positive in 3+ and ISH-
positive 2+ cases. HER2 status using DIA was com-
pared to HER2 status with standard diagnostics
(manual scoring with ISH in 2+ cases). Interplatform
agreement of IHC scores was ‘moderate’ (linear
weighted j = 0.58), agreement between manual
scoring and platform A was ‘moderate’ (j = 0.60)
and between manual scoring and platform B ‘almost
perfect’ (j = 0.85). Compared to manual scoring, DIA
resulted in a reduction of 2+ cases from 17.1 to 1.3%
with platform A and from 17.1 to 15.8% with plat-
form B. However, compared to standard diagnostics,
there were three false-negative cases with DIA using
platform A [81.3% sensitivity, 100% specificity,
100% positive predictive value (PPV), 97.8% negative
predictive value (NPV)]. Sensitivity, specificity, PPV
and NPV were 100% with DIA using platform B.
Conclusions: DIA of HER2 IHC is a valid tool in deter-
mining HER2 status in breast carcinoma. Algorithms
in different platforms can behave differently, and opti-
mal calibration is essential. In clinical practice, DIA
offers an objective alternative to manual scoring, but a
reduction in 2+ cases could result in loss of sensitivity.
Keywords: breast cancer, digital image analysis (DIA), human epidermal growth factor 2 (HER2),
immunohistochemistry (IHC)
Introduction
Human epidermal growth factor receptor 2 (HER2/
ErbB2) is a prognostic and predictive biomarker in
breast cancer, and HER2 testing is standard of
care.1,2 HER2 is overexpressed and/or amplified in
15–20% of breast cancers.1 HER2-positivity is
required for targeted anti-HER2-therapy with drugs
such as trastuzumab, pertuzumab and lapatinib.3–6
HER2 status is determined by semiquantitative assess-
ment of cell membrane overexpression with immuno-
histochemistry (IHC) or by assessing gene
amplification with in-situ hybridisation (ISH). In daily
practice, a two-tiered method is applied: IHC score 0/
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1+ is negative; 2+ equivocal and 3+ positive; ISH fol-
lows only in 2+ cases.2
IHC is scored subjectively by individual patholo-
gists, and interobserver variability occurs.7,8 Recently,
digital image analysis (DIA) has emerged as an objec-
tive and reproducible IHC scoring method.9–13 The
American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guideline for
HER2 has acknowledged DIA as a diagnostic modal-
ity.2 DIA could reduce the number of 2+ cases requir-
ing subsequent ISH testing, which may increase time-
and cost-efficiency in clinical practice.12–14 Our group
previously found that DIA of HER2 IHC can reduce
2+ cases in gastroesophageal adenocarcinoma.15
Studies to date have compared manual scoring
with DIA by different platforms, each using only one
platform.9–17 However, interplatform variability may
be expected because these platforms use different
algorithms, each with unique approaches to classify-
ing tissue and cellular components.18–20 To our
knowledge, no study to date has examined HER2 DIA
interplatform agreement.
We conducted a study on DIA of HER2 IHC in breast
carcinoma. First, we aimed to assess interplatform
agreement by two independent platforms. Secondly,
we aimed to validate DIA and evaluate the added value
of DIA in clinical practice by comparing DIA with man-
ual scoring and comparing HER2 status outcome using
DIA (with ISH on 2+ cases) with standard diagnostics
(manual scoring with ISH on 2+ cases).
Materials and methods
C A S E S
Resection specimens of 152 consecutive primary
invasive breast carcinomas from the University Medi-
cal Center Groningen (the Netherlands) treated
between August 2015 and February 2017 were
included. IHC and ISH were performed on 3 lm sec-
tions, cut from formalin-fixed paraffin-embedded
tumour blocks. Standardised HER2 controls were
included in all IHC and ISH tests.
Patient material was handled following the Dutch
‘Code of conduct for medical research’.21 Therefore,
no additional Ethics Committee permission was
required.
I M M U N O H I S T O C H E M I S T R Y
IHC was performed using SP3 (rabbit monoclonal
antibody; Thermo Fisher Scientific, Fremont, CA,
USA) on the BenchMark Ultra (Ventana Medical
Systems, Illkirch, France), with antibody dilution
1:40; antigen retrieval time 64 min (95°C, CC1, pH9;
Ventana) and primary antibody incubation time
32 min. Visualisation was achieved with the ultra-
View diaminobenzidine (DAB) detection kit (Ventana)
and antigen amplification was applied (Ventana
amplification kit). Counterstaining was performed
with Mayer’s haematoxylin (Klinipath, Breda, the
Netherlands).
M A N U A L S C O R I N G
HER2 IHC was scored independently by an experi-
enced pathologist (B.V.) and a senior resident (T.K.),
according to current guidelines:2 0 (negative): no
staining or faint/barely perceptible incomplete mem-
brane staining in ≤10% of tumour cells; 1+ (nega-
tive): faint/barely perceptible incomplete membrane
staining in >10%; 2+ (equivocal): weak/moderate
complete membrane staining in >10%; and 3+ (posi-
tive): circumferential complete intense membrane
staining in >10%. Discordant cases were re-evaluated
by both observers to establish a consensus manual
score. This occurred in only 13 of 152 cases (8.6%)
and discordance was only 1 score point in these
cases.
I M A G E A C Q U I S I T I O N A N D D I A P L A T F O R M S
Glass slides were scanned in a Philips Ultra Fast Scan-
ner 1.6 (Philips, Eindhoven, the Netherlands) with a
940 magnification lens, using a single-focus layer
without Z-stacking. Tissue detection with focus points
was applied automatically to obtain the optimal
image. Digitised slides were stored on a centralised
server and a direct link was established in both DIA
platforms. The platforms were Visiopharm Integrator
System (VIS) version 6.9.0.2779 (Visiopharm, Hør-
sholm, Denmark) and HALO version 2.0.1061 (Indica
Labs, Corrales, NM, USA).
D I G I T A L I M A G E A N A L Y S I S
HER2 IHC was scored using HER2 algorithms in both
platforms.
The HER2-CONNECT algorithm in the VIS platform
analyses membrane staining by calculating a connec-
tivity value based on DAB staining of linear struc-
tures corresponding to membrane fragments.13 This
connectivity value can vary continuously from 0 to
1, and is converted to a HER2 score with specific cut-
offs. Standardised recommended cut-offs were applied:
0: connectivity = 0; 1+: 0 < connectivity ≤ 0.40; 2+:
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0.40 < connectivity ≤ 0.64; 3+: connectivity > 0.64.
HER2-CONNECT is a CE-IVD-approved and NordiQC-
validated algorithm, and was not further calibrated
for this study.
The HALO platform algorithm was constructed
using the HER2 module (version 1.1), which mea-
sures membranous staining on a cell-by-cell basis.
The algorithm was calibrated in close collaboration
between the researcher (T.K.) and the platform ven-
dor, using a training set of 20 randomly selected
breast carcinomas resected in January–August 2015,
identically handled and stained but not included in
the current study. Variables including colour classifi-
cation, cell classification, membrane detection and
membrane completeness were optimised in the cali-
bration process. Cell-specific HER2 classification was
based on specific cut-offs in HER2 optical density
(OD), calibrated at 0: 0 < OD ≤ 0.085; 1+:
0.085 < OD ≤ 0.160; 2+: 0.160 < OD ≤ 0.259; and
3+: OD > 0.259. The HER2 score was based on
>10% of the highest classification score within all
classified cells.
In accordance with both platform vendors’ recom-
mendations, HER2 analysis was performed on three
annotated areas (1.5 mm2 regions at 9100 magnifi-
cation) representative of the whole tumour. The high-
est HER2 score in at least one area was taken as the
HER2 score for each case.
I N - S I T U H Y B R I D I S A T I O N
Fluorescence in-situ hybridisation (FISH, n = 32,
PathVysion HER2 DNA Probe Kit; Abbott Molecular,
Abbott Park, IL, USA) and/or bright-field dual-colour
silver in-situ hybridisation (SISH, n = 126, INFORM
HER2 Dual ISH DNA Probe Cocktail; Ventana) assays
were performed following the manufacturer’s recom-
mendations.
ISH was evaluated according to current guidelines,
calculating the HER2/CEP17 ratio and the average
HER2 copy number in 20–40 cells.2 ISH-positive:
ratio ≥2.0 with HER2 ≥4.0, or ratio <2.0 with HER2
≥6.0 by two observers with FISH and SISH. ISH-nega-
tive: ratio <2.0 with HER2 <4.0, ratio ≥2.0 with
HER2 <4.0 by two observers with FISH and SISH, or
ratio <2.0 with HER2 ≥4.0/<6.0 by two observers
with FISH and SISH (this last category was ‘equivo-
cal’ before the recent guideline update).1,2
S T A T I S T I C S
To establish interplatform agreement, linear weighted
kappa (j) statistics were performed in R for Windows
version 3.3.2 (R Foundation for Statistical Comput-
ing, Vienna, Austria), using the ‘irr’-package for j
statistics. j was interpreted as <0.2, slight; 0.21–
0.40, fair; 0.41–0.60, moderate; 0.61–0.80, substan-
tial; and 0.81–1.00, almost perfect agreement.22
To validate DIA and to evaluate the added value of
DIA in clinical practice, we calculated j for agree-
ment between DIA and manual scoring and calcu-
lated sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) for HER2
status outcome using DIA (with ISH on 2+ cases)
with standard diagnostics (manual scoring with ISH
on 2+ cases) as a reference.
Results
I M M U N O H I S T O C H E M I S T R Y A N D A G R E E M E N T
IHC with DIA images are shown in Figure 1. By DIA
in platform A on all 152 cases, 139 cases were 0/1+
(91.4%), two were 2+ (1.3%) and 11 were 3+ (7.2%).
By DIA in platform B, 114 cases were 0/1+ (75%), 24
were 2+ (15.8%) and 14 were 3+ (9.2%). Interplat-
form agreement was ‘moderate’ (j = 0.58, 82.2%). By
manual scoring, 114 cases were 0/1+ (75%), 26 were
2+ (17.1%) and 12 were 3+ (7.9%). As such, DIA in
platform A resulted in a 15.8% reduction of 2+ cases
(26 to two cases, 17.1–1.3%) compared to manual
scoring, which was 1.3% with platform B (26–24
cases, 17.1–15.8%). Table 1 displays cross-tabulations
of HER2 scores. Agreement was ‘moderate’ between
manual scoring and platform A (j = 0.60, 82.9%),
comparable to interplatform agreement. Agreement
was ‘almost perfect’ between manual scoring and plat-
form B (j = 0.85, 91.1%).
C O N C O R D A N C E W I T H S T A N D A R D D I A G N O S T I C S
HER2-positivity by standard diagnostics was 10.5% (16
of 152 cases), by platform A 8.6% (13 cases) and by
platform B 10.5% (16 cases). IHC/ISH concordance of
manual scoring and DIA is shown in Table 2. HER2 sta-
tus outcome using DIA compared to standard diagnos-
tics is displayed in Table 3. Specificity, sensitivity, PPV
and NPV of HER2 status outcome using DIA, with stan-
dard diagnostics as a reference, are shown in Table 4.
Platform B had no false-positive or false-negative cases.
In platform A, three cases were false-negative, as these
cases were HER2-positive with standard diagnostics
(manual IHC 2+, ISH-positive, in all three cases). These
cases would have been missed in clinical practice, as the
IHC-negative score would not have prompted subse-
quent ISH. Interestingly, ISH was near the cut-offs for
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 917–924.
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amplification. Case 1 showed HER2/CEP17 ratio 2.2
(just above the 2.0 cut-off), with HER2 copy number
5.5. Case 2 showed ratio 1.2, but HER2 copy number
6.5 (just above the 6.0 cut-off). Similarly, case 3 showed
ratio 1.8 with HER2 copy number 7.2. In all three cases,
FISH and SISH showed identical results. With DIA in
platform B, case 1 was 3+ and cases 2 and 3 were 2+.
Figure 2 displays the three false-negative cases.
Discussion
We aimed first to compare DIA of HER2 IHC by two
platforms and secondly to validate DIA and evaluate
the added value of DIA in clinical practice. We found
moderate interplatform agreement. One platform per-
formed comparable to standard diagnostics, with
100% sensitivity and specificity, high agreement with
manual scoring, but without a reduction of 2+ cases.
The other platform significantly reduced 2+ cases, but
at the cost of three false-negative cases, with slight
sensitivity loss.
HER2-positive breast cancers are eligible for anti-
HER2 therapy and appropriate HER2 testing is crucial
for adequate treatment.2–6 HER2-positivity in our
study was 10.5%, which is somewhat lower than the
15–20% HER2-positivity rate reported in the litera-
ture.2 An explanation for this difference might be
that we included surgical resection specimens
obtained in our academic hospital, in which the
patient population may differ from general hospitals.
To the best of our knowledge, our study is the first
to assess interplatform agreement between HER2
algorithms in different DIA platforms. Interplatform




Figure 1. Digital image analysis of HER2 immunohistochemistry by two DIA platforms. HER2 score 1+ (A–C), score 2+ (D–F) and score 3+
(G–I). Images without DIA mark-up (left column), with DIA in platform A (middle column) and with DIA in platform B (right column).
HER2, human epidermal growth factor 2; DIA, digital image analysis. [Colour figure can be viewed at wileyonlinelibrary.com]
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 917–924.
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unique algorithms with differences in classifying tis-
sue morphology, cellular characteristics and staining
patterns.18–20 This could lead to different HER2
scores in different platforms. A recent study on
another biomarker, Ki67, showed high interplatform
agreement (R2 = 0.97, Spearman’s q = 0.96, numeri-
cal scoring).20 In the current study, we found that
HER2 algorithms of different DIA platforms behaved
differently, with only ‘moderate’ interplatform agree-
ment (82.2%, j = 0.58, ordinal scoring). This was
comparable to the ‘moderate’ agreement between
manual scoring and platform A, which could be anal-
ogous to the ‘almost perfect’ agreement between
manual scoring and platform B.
Table 1. Comparison of HER2 IHC scores by manual scor-
ing and DIA
Manual scoring
0/1+ 2+ 3+ Total
Platform A DIA
0/1+ 114 25 0 139
2+ 0 1 1 2
3+ 0 0 11 11
Total 114 26 12 152
j = 0.60
Manual scoring
0/1+ 2+ 3+ Total
Platform B DIA
0/1+ 109 5 0 114
2+ 5 19 0 24
3+ 0 2 12 14
Total 114 26 12 152
j = 0.85
Platform B DIA
0/1+ 2+ 3+ Total
Platform A DIA
0/1+ 114 24 1 139
2+ 0 0 2 2
3+ 0 0 11 11
Total 114 24 14 152
j = 0.58
HER2, human epidermal growth factor 2; IHC, immunohistochem-
istry; DIA, digital image analysis; j, linear weighted kappa.




0/1+ 114 0 114
2+ 22 4 26
3+ 0 12 12
Total 136 16 152
Platform A DIA
0/1+ 136 3 139
2+ 0 2 2
3+ 0 11 11
Total 136 16 152
Platform B DIA
0/1+ 114 0 114
2+ 22 2 24
3+ 0 14 14
Total 136 16 152
IHC, immunohistochemistry; ISH, in-situ hybridisation; DIA, digital
image analysis.





Negative 136 3 139
Positive 0 13 13
Total 136 16 152
Platform B DIA
Negative 136 0 136
Positive 0 16 16
Total 136 16 152
HER2, human epidermal growth factor 2; IHC, immunohistochem-
istry; DIA, digital image analysis.
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 917–924.
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The difference between platforms in our study
could be related to the calibration process. Optimal
calibration is essential for any DIA algorithm, as algo-
rithms are influenced by colour and texture varia-
tions due to differences in materials and staining
processes among laboratories.23 For platform A, the
standardised CE-IVD-approved and NordiQC-validated
HER2-CONNECT algorithm was used without modifi-
cations.24 For platform B, the algorithm was cali-
brated intensively, and various variables including
cut-off values were optimised in close collaboration
between the researcher and the platform vendor. This
could explain the much higher agreement between
manual scoring and platform B than between manual
scoring and platform A. Our results show that an
‘off-the-shelf’ approved and validated product will not
necessarily perform as well as the gold standard
(manual assessment). Algorithms need to be adjusted
to a local laboratory’s IHC and background staining
intensities and digital image quality. In turn, labora-
tories must produce quality IHC slides for DIA to
work. To ensure this, laboratories must abide by gen-
eral quality assurance rules (e.g. fixation and IHC
parameters) and participate in external technical
quality assurance programmes.
Differences between platforms could also be related
to the parameters assessed by an algorithm and to
the cut-offs on which HER2 classification is based. In
our study, one platform uses membrane completeness
(‘connectivity’)-based cut-offs, while the other uses
strength of staining (‘optical density’)-based cut-offs.
However, both parameters are incorporated in the
underlying HER2 algorithms of both platforms.
Studies to date have shown high agreement
between manual scoring and DIA of HER2 IHC in
breast cancer, with 87.5–94.2% agreement rates
(weighted j = 0.80–0.92, Cohen’s j = 0.74–
0.86).10–14,16,17 We found comparable agreement
between manual scoring and platform B: 91.1%
agreement, weighted j = 0.85 (when calculated,
Cohen’s j = 0.80). Agreement was lower between
manual scoring and platform A: 82.9% agreement,
weighted j = 0.60 (when calculated, Cohen’s
j = 0.44). The reason for disagreement was the
reduction of 2+ cases with platform A.
The reduction of 2+ cases with DIA in platform A
resulted in three false-negative cases (of 152 cases).
Sensitivity was 81.3%, NPV was 97.8% and speci-
ficity and PPV were 100%. Platform B had 100%
sensitivity, specificity, PPV and NPV. Earlier studies
also had false-negative and/or false-positive
cases.10,12–14 Helin et al. reported six false-negative-
and six false-positive cases in 750 cases and Dobson
et al. reported six false-negative- and no false-positive
cases in 136 cases. Both studies used different plat-
forms than we did, and did not report sensitivity and
specificity. Holten-Rossing et al. used one of the plat-
forms in our study (VIS), and reported a 68%
Table 4. Sensitivity, specificity and predictive values for
HER2 status outcome using DIA (with ISH on 2+ cases),
compared to standard diagnostics (manual scoring with ISH













81.3 100 100 97.8 1.3 (n = 2)
Platform
B DIA
100 100 100 100 15.8 (n = 24)
HER2, human epidermal growth factor 2; DIA, digital image analy-
sis; ISH, in-situ hybridisation; PPV, positive predictive value; NPV,
negative predictive value; IHC, immunohistochemistry.
A B C
Figure 2. HER2 immunohistochemistry images of the three cases which were false-negative with DIA in platform A (connectivity scores: A
0.38, B 0.08, C 0.10). All cases were scored 1+ by platform A but showed HER2 amplification with ISH. Manual scores were 2+ in all cases.
In platform B, scores were 3+ (A) and 2+ (B, C). HER2, human epidermal growth factor 2; DIA, digital image analysis; ISH, in-situ
hybridisation. [Colour figure can be viewed at wileyonlinelibrary.com]
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reduction of 2+ cases, with 99.2% specificity and
100% sensitivity.14 However, sensitivity and speci-
ficity in their study cannot be compared to our study
because they were calculated differently: they used
ISH as a reference for IHC 0/1+ and 3+ only; 2+
cases were excluded because 2+ is ‘equivocal’ and
therefore not predictive of ISH, which is the downside
of using ISH as a reference. Our study’s analysis was
more clinically orientated, as we included all IHC
cases and used standard diagnostics as a reference
(manual IHC with ISH on 2+ cases). However, with
ISH as a reference, results would be comparable
because ISH was concordant with manual scoring in
our study.
In previous studies we have shown the added
value of DIA in clinical practice. DIA of Ki67 IHC in
breast carcinoma offers a time-saving and repro-
ducible alternative to manual counting.20 Addition-
ally, DIA of HER2 IHC in gastroesophageal
adenocarcinomas proved to be a reliable alternative
to manual scoring, reducing 2+ cases with high sen-
sitivity (93.8–97.9%) and specificity (99.6%).15 How-
ever, in comparison to breast carcinoma, HER2
scoring in gastroesophageal carcinoma is prone to
more manual 2+ cases due to tumour heterogeneity
and a low positivity threshold in biopsies (≥5 tumour
cell clusters are sufficient). Considering our current
findings, the added value of DIA of HER2 IHC in
breast carcinoma is more questionable. Because
pathologists can evaluate HER2 slides within sec-
onds, increasing time-efficiency has less potential
gain compared to, for example, DIA of Ki67,20 unless
it is applied to a large number of cases. A reduction
of 2+ cases would be of greater added value, as this
reduces subsequent ISH tests and thus increases
time- and cost-efficiency in clinical practice. How-
ever, the 2+ case reduction in platform A in our
study (26 to two cases) led to three false-negative
cases, which is clinically undesirable, because these
patients would consequently not receive the anti-
HER2-therapy to which they are entitled. Therefore,
despite high sensitivity and specificity, the clinical
application of platform A as calibrated in this study
is debatable. While there were no false-negative cases
in platform B, the reduction of 2+ cases was mar-
ginal (26–24 cases), and therefore of little added
value in clinical practice. As such, the true benefit of
DIA of HER2 in breast cancer is that it offers an
objective scoring method which is not subject to
intra-observer variability, as every analysis is based
on set algorithmic settings. Therefore, DIA could
increase HER2 scoring reproducibility by aiding
pathologists in reducing intra- and interobserver
variability. However, the question is whether this
benefit would justify purchasing a potentially expen-
sive DIA platform.
In current clinical practice, receptor status determi-
nation is more commonly performed on biopsies.
While our study was performed on resection speci-
mens, we believe that the results of this study can be
extended to biopsies, because areas for DIA would be
annotated in a similar fashion in biopsies. Addition-
ally, studies show that concordance for HER2 testing
is high between biopsies and resection specimens.25
In conclusion, we have shown that DIA of HER2
IHC in breast carcinoma is a feasible alternative to
manual scoring and a valid tool to determine HER2
status with high sensitivity, and sensitivity when
compared to standard diagnostics. However, algo-
rithms in different platforms can behave differently,
and optimal calibration is essential to introduce this
technique safely in daily practice. One platform per-
formed similarly but not better than standard diag-
nostics, while a reduction of 2+ cases by the other
platform resulted in a slight but clinically undesirable
loss of sensitivity. Therefore, while DIA of HER2 IHC
in breast carcinoma offers an objective alternative to
manual scoring, which could potentially increase
HER2 scoring reproducibility in clinical practice, its
added value in reducing 2+ cases is debatable.
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